Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

When a fan of a cult anime series wanted to watch its episodes in every possible order, they asked a question that had perplexed combinatorial mathematicians for years ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

Vertex's total revenues for Q4 2024 were $ ... under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, to be filed with the ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ ... heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, to be filed with the ...

The end of the Vertex-Verve collaboration comes as investors are reevaluating once sky-high expectations for the gene editing industry as commercial realities set in. Shares of Verve and top companies ...

Data supplied by Morningstar and accurate on Sep 30, 2024. It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of ...

A 1099 form is a record that an entity or person (not your employer) gave or paid you money. One copy goes to you and another copy goes to the IRS. Many, or all, of the products featured on this ...